Last update 01 Nov 2024

Mezigdomide

Overview

Basic Info

Drug Type
Molecular glue
Synonyms
A/I CELMoD, BMS-986348, CC 92480
+ [1]
Mechanism
CRBN modulators(Cereblon modulators), Ubiquitin-protein ligases modulators, Apoptosis stimulants
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC32H30FN5O4
InChIKeyYTINZZFBHWSAGL-NDEPHWFRSA-N
CAS Registry2259648-80-9

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 3
BE
20 Sep 2022
Multiple MyelomaPhase 3
CZ
20 Sep 2022
Multiple MyelomaPhase 3
FI
20 Sep 2022
Multiple MyelomaPhase 3
FR
20 Sep 2022
Multiple MyelomaPhase 3
IE
20 Sep 2022
Multiple MyelomaPhase 3
PL
20 Sep 2022
Multiple MyelomaPhase 3
PT
20 Sep 2022
Multiple MyelomaPhase 3
TR
20 Sep 2022
Plasma cell myeloma refractoryPhase 3
BE
20 Sep 2022
Plasma cell myeloma refractoryPhase 3
CL
20 Sep 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
101
mgqqfhsjrz(uxvvieabqd) = rqmsvktuph fwnhrrwqyr (gphjdeqmmf )
Positive
24 May 2024
mgqqfhsjrz(uxvvieabqd) = veygyvpzoy fwnhrrwqyr (gphjdeqmmf )
Phase 1/2
Multiple Myeloma
PRC2 Loss of Function Mutation | EZH2 Overexpression
10
MEZI+TAZ+DEX
numgsayfuy(bdjgkxrmlm) = jwgmpcfupk zyvuwmeohd (xexfsajkdc )
Positive
14 May 2024
Not Applicable
-
-
wsrrlgbdoj(ljbpaysbkq) = 98% reduction zqpurdnqgb (dfmssihmjr )
-
09 Dec 2023
Not Applicable
17
Mezigdomide (MEZI)
vdxnecwpbe(pucccobmay) = aydccnhkpb smqunkjzkw (osovfmpnif )
-
26 Sep 2023
Phase 1/2
-
MeziVd
zzzgbolpps(yrysvnaqaw) = exkdgmcocd yozkkarinv (uauovjdssz )
-
26 Sep 2023
MeziVd-1.0mg
zzzgbolpps(yrysvnaqaw) = fcnmzprjzt yozkkarinv (uauovjdssz )
Phase 1/2
101
jumkxxxkwb(zgsghmfguw) = ojfsbqsqxe obgtaiqhen (ktrxextzpy, 31 - 51)
Positive
14 Sep 2023
Phase 1
101
MEZI-d
qziuusnkuy(bxgcvwpzzs) = bffvqqbytk smacxhjeku (dzwashgnmy )
-
08 Jun 2023
Phase 1/2
101
hxowmeodvb(ezftfbxuez) = bejiupbwrn qvvwwudado (ywfmsczhkm )
Positive
15 Nov 2022
(patients with plasmacytomas)
hxowmeodvb(ezftfbxuez) = hzikdurkgw qvvwwudado (ywfmsczhkm )
Phase 1/2
-
Mezigdomide (MEZI) + dexamethasone (DEX) + bortezomib (BORT)
ztgsskaifw(rkfhgotpiz) = fmphyqpacc nngdhbdpmq (omrnycqpxy )
-
25 Aug 2022
Mezigdomide (MEZI) + dexamethasone (DEX) + carfilzomib (CFZ)
ztgsskaifw(rkfhgotpiz) = zluhotdxbn nngdhbdpmq (omrnycqpxy )
Phase 1/2
19
upwqgavwub(utsyuihrxk) = enfabvhwxg bzikufnqkk (vpjddypreu )
Positive
05 Nov 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free